Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Investigation of genes influencing response to treatment with Infliximab, Etanercept and Adalumimab in patients with rheumatoid arthritis and related arthropathies.

Trial Profile

Investigation of genes influencing response to treatment with Infliximab, Etanercept and Adalumimab in patients with rheumatoid arthritis and related arthropathies.

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Infliximab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms BRAGGSS
  • Most Recent Events

    • 04 Jun 2022 Results assessing impact of Covid-19 on medication non-adherence in a rheumatoid and psoriatic arthritis in a UK cohort from two multicentre observational studies: BRAGGSS and OUTPASS presented at the 23rd Annual Congress of the European League Against Rheumatism
    • 31 May 2020 Results (n=2991) evaluating Latent class trajectory modelling of 2-components-DAS28 identifies multiple rheumatoid arthritis phenotypes of response to biologic disease modifying anti-rheumatic drugs, published in the Arthritis and Rheumatology
    • 17 Jun 2017 Results identifying Biomarkers to predict the response to etanercept and adalimumab therapy (n=125), presented at the 18th Annual Congress of the European League Against Rheumatism
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top